Online inquiry

IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5201MR)

This product GTTS-WQ5201MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD22 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Hairy cell leukemia (HCL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_001185099.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 933
UniProt ID P20273
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5201MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10475MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-2951742
GTTS-WQ6416MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CT-011
GTTS-WQ4296MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BIIB-054
GTTS-WQ1526MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-031
GTTS-WQ4583MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986004
GTTS-WQ7346MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FPA-150
GTTS-WQ11364MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-573
GTTS-WQ9622MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-63723283
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW